- SIGA Technologies stock soared 43% on Friday.
- SIGA stock is up another 30% in Monday's premarket.
- SIGA has a monkeypox vaccine candidate that got FDA approval.
SIGA Technologies is soaring again on Monday as the company continues to benefit from the spread of monkeypox throughout the globe. Monkeypox is a viral infection that was common in West Africa but has now been identified globally. Initial cases are relatively small, but the wide geographical spread means that the number of cases is likely to grow. Monkeypox has been likened to chickenpox or smallpox, and it is for this reason that SIGA shares have been in demand. SIGA Technologies makes a smallpox treatment. Smallpox treatments will be effective for the treatment of monkeypox, according to experts, as monkeypox is in the same viral family.
SIGA Technologies stock news
SIGA stock and others involved with monkeypox or smallpox vaccines saw impressive gains last week. The WHO said last week it was concerned about the spread of the disease throughout summer in Europe.
"As we enter the summer season in the European region, with mass gatherings, festivals and parties, I am concerned that transmission could accelerate, as the cases currently being detected are among those engaging in sexual activity, and the symptoms are unfamiliar to many," Dr. Hans Henri P. Kluge, the WHOs Regional Director for Europe.
The US has already confirmed at least one case of the virus with Europe reporting several. The disease is native to West Africa. Last week the US FDA approved the intravenous use of SIGA's TPoxx treatment as an addition to the already approved use as an oral solution to smallpox. SIGA stock also gained last week as the US Department of Defense awarded SIGA a $7.5 million contract for the supply of oral TPOXX. This was in addition to a $26 million contract SIGA already has with the Department of Defense.
Other notable gainers in the space are Tonix Pharma (TNXP) and Emergent Bio (EBS).
SIGA stock chart
SIGA stock chart, weekly
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.